1887
  1. Home
  2. A-Z Publications
  3. Global Cardiology Science and Practice
  4. Volume 2013, Issue 3
  5. Article
Volume 2013, Issue 3
  • ISSN: 2305-7823
  • EISSN:

Abstract

Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition characterized by variable degrees of asymmetric left ventricular (LV) hypertrophy, generally associated with mutations in sarcomere protein genes. While generally perceived as rare, HCM is the most common genetic heart disease with over one million affected individuals in Europe alone and represents a prevalent cause of sudden cardiac death in the young. To date, HCM remains an orphan disease, as recommended treatment strategies are based on the empirical use of old drugs with little evidence supporting their clinical benefit in this context. In the six decades since the original description of the disease, less than fifty pharmacological studies have been performed in HCM patients, enrolling little over 2,000 HCM patients, mostly comprising small non-randomized cohorts. No specific agent has been convincingly shown to affect outcome, and critical issues such as prevention of myocardial energy depletion, microvascular ischemia, progressive myocardial fibrosis and the peculiar mechanisms of arrhythmogenesis in HCM still need to be addressed in a systematic fashion. However, there is increasing evidence that a variety of drugs may counter the effects of sarcomere protein mutations and the resulting pathophysiological abnormalities at the molecular, cellular and organ level. Following major advances in our understanding of HCM and increasing opportunities for networking among large international referral centres, the opportunity now exists to identify potentially effective treatments and implement adequately designed pharmacological trials, with the ultimate aim to impact the natural course of the disease, alleviate symptoms and improve quality of life in our patients.

© 2013 Olivotto, Tomberli, Spoladore, Mugelli, Cecchi, Camici, licensee Bloomsbury Qatar Foundation Journals.
Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2013.31
2013-12-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2013/3/gcsp.2013.31.html?itemId=/content/journals/10.5339/gcsp.2013.31&mimeType=html&fmt=ahah

References

  1. Braunwald E. Cardiovascular science: opportunities for translating research into improved care. J Clin Invest. 2013; 123::6–10.
     [Google Scholar]
  2. Maron BJ, Braunwald E. Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease. Circulation. 2012; 126::1640–1644.
     [Google Scholar]
  3. Marian AJ. Experimental therapies in hypertrophic cardiomyopathy. J CardiovascTransl Res. 2009; 2::483–492.
     [Google Scholar]
  4. Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012; 33::1724–1733.
     [Google Scholar]
  5. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy; executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124::2761–2796.
     [Google Scholar]
  6. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septalmyectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am CollCardiol. 2005; 46::470–476.
     [Google Scholar]
  7. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010; 122:11:1130–1133.
     [Google Scholar]
  8. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol. 2012; 9::91–100.
     [Google Scholar]
  9. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012; 5::535–546.
     [Google Scholar]
  10. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006; 114::2232–2239.
     [Google Scholar]
  11. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005; 45::1251–1258.
     [Google Scholar]
  12. Binder J, Ommen SR, Sorajja P, Nishimura RA, Tajik AJ. Clinical and echocardiographic variables fail to predict response to dual-chamber pacing for hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2008; 21::796–800.
     [Google Scholar]
  13. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Coan SD, Seidman JG, Diez J, Seidman CE. Myocardialfibrosisas an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010; 363::552–563.
     [Google Scholar]
  14. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006; 114::216–225.
     [Google Scholar]
  15. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012; 5::552–559.
     [Google Scholar]
  16. Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007; 50::831–834.
     [Google Scholar]
  17. Penicka M, Gregor P, Kerekes R, Marek D, Curila K, Krupicka J, Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study Investigators . The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn. 2009; 11::35–41.
     [Google Scholar]
  18. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010; 122::1562–1569.
     [Google Scholar]
  19. Coats CJ, Gallagher MJ, Foley M, O'Mahony C, Critoph C, Gimeno J, Dawnay A, McKenna WJ, Elliott PM. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J. 2013; 34:32:2529–2537. doi:10.1093/eurheartj/eht070 .
     [Google Scholar]
  20. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012; 52::857–864.
     [Google Scholar]
  21. Mourad J, Hanon O, Deverre JR, Camici PG, Sellier P, Duboc D, Safar ME. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low dose ace-inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst. 2003; 4::94–95.
     [Google Scholar]
  22. Neglia D, Fommei E, Varela-Carver A, Mancini M, Ghione S, Lombardi M, Pisani P, Parker H, D'Amati G, Donato L, Camici PG. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens. 2011; 29::364–372.
     [Google Scholar]
  23. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012; 14::13. doi: 10.1186/1532-429X-14-13 .
     [Google Scholar]
  24. Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT, Fabry Outcome Survey investigators . Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet. 2009; 374::1986–1996.
     [Google Scholar]
  25. http://www.myokardia.com/approach-programs.php accessed on 31/04/2013.
  26. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Yacoub M, Olivotto I, Belardinelli L, Poggesi C, Cerbai E, Mugelli A. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013; 127::575–584.
     [Google Scholar]
  27. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013; 12::101–113.
     [Google Scholar]
  28. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011; 331::1439–1443.
     [Google Scholar]
  29. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, Thiene G, Iliceto S. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007; 93::708–710.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2013.31
Loading
Hypertrophic cardiomyopathy: The need for randomized trials
Global Cardiology Science and Practice 2013, 31 (2013); https://doi.org/10.5339/gcsp.2013.31
/content/journals/10.5339/gcsp.2013.31
/content/journals/10.5339/gcsp.2013.31
Loading

Data & Media loading...

Supplements

Supplementary File 1

  • Article Type: Review Article
Keyword(s): clinical trials, hypertrophic cardiomyopathy, outcome, pharmacological therapy and translational research
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error